CAR T-cell Therapy Market (Product Type: Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Lisocabtagene Maraleucel, Idecabtagene Vicleucel, and Others; Indication: Acute Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Multiple Myeloma, and Others; and End-user: Hospitals and Cancer Treatment Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2030

Description

Continuity in Provision of Medical Products Gains Importance During COVID-19 Outbreak

The coronavirus outbreak has generated a significant repercussion on the administration of adoptive cell therapies, including chimeric antigen receptor (CAR) T-cells. Decline in people transit, closing of borders, and confinement of the population has impacted the supply chains of these life-saving medical products. This is anticipated to slowdown the growth of the CAR T-cell therapy market during the ongoing pandemic.

Although hospitals have been compelled to change their usual workflows to cope with the saturation of health services by hospitalized patients, stakeholders in the CAR T-cell therapy market are increasing efforts to ensure continuity in offering the treatment. This is prominent in the case of patients with relapsed/refractory hematologic malignancies. Moreover, the burgeoning growth of telehealth services is encouraging early intervention to attenuate neurotoxicity or cytokine release syndrome with tocilizumab and prophylactic/preventive strategies to prevent infection.

Stakeholders Employ Innovative CAR Engineering Strategies to Improve Treatment Efficacy

The CAR T-cell therapy market is expected to clock a CAGR of 30.6% during the assessment period. The CAR T-cell therapy is known as a revolutionary treatment option for cancer, owing to its remarkably effective and durable clinical responses. However, market stakeholders need to address major limitations to the CAR T-cell therapy, which involves life-threatening CAR T-cell associated toxicities, limited persistence, and issues such as low efficacy against solid tumors. Hence, stakeholders are increasing their research capabilities to combine the CAR T-cell therapy with other anticancer therapies.

Stakeholders in the CAR T-cell therapy market are anticipated to collaborate with researchers, scientists, and biotechnologists to employ innovative CAR engineering strategies in order to improve anti-tumor efficacy, expand clinical efficacy, and limit toxicities. Stakeholders are increasing efforts to improve clinical efficacy in both hematological malignancy and solid tumors to overcome treatment limitations.

In Vivo Gene Delivery to Immune Cells Shows Potential to Improve Medical Outcomes

Several hundred clinical trials of CAR-T have been registered and actively recruiting patients with various malignant & non-malignant conditions are showing rapid pace of innovation in this field. However, substantial challenges currently limit its widespread adoption. The CAR T-cell therapy is potentially expensive with both tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel) in the U.S. when used for high-grade B-cell lymphomas. Hence, stakeholders in the CAR T-cell therapy market are increasing efforts to reduce cost in order to meet the expanding indications of CAR-T.

Publically funded healthcare systems where resource allocation is strained, healthcare providers are striving to reduce treatment cost for CAR-T. Companies in the CAR T-cell therapy market are gaining awareness about novel strategies such as in vivo gene delivery to immune cells using nanoparticles to improve medical outcomes.

Stringent Regulations for Manufacturing CAR T-Cells Ensure Patient Safety

The CAR T-cell therapy market is projected to mature from a revenue of US$ 1.1 Bn in 2020 and reach US$ 21.8 Bn by 2031. From regulatory point of view, CAR T-cells are an advanced therapy medicinal product (ATMP) in the European Union (EU). Companies are increasing the availability of tissue-engineered products, gene therapy medicinal products, and somatic cell therapy medicinal products, among others. Such products are playing a crucial role in the treatment of cancer and hereditary diseases as well as in regenerative medicine.

CAR T-cells as an ATMP can be generated by either viral transduction, leading to a permanent CAR expression or by using mRNA. Companies in the CAR T-cell therapy market are increasing R&D investments in this field of the study. Manufacturing, approvals, and regulations of these therapies are potentially complex to protect patients.

Immunotherapy Helps in Treatment of New and Difficult Cancer Indications

The immunotherapy industry is an ever-evolving landscape with interest in CAR T-cells, checkpoint inhibitors, and bispecific antibodies exploding in the recent years. Likewise, Ceylad Oncology - a clinical stage biotechnology company, is gaining recognition for increasing its focus on CAR T-cell therapies, which involve engineering patient or donor T cells to display a CAR that targets the immune cells to cancer cells via antigen receptor binding. Such innovations are helping healthcare providers to treat new and difficult cancer indications, including solid tumors, and harness the immune system in a novel way to target new pathways.

Companies in the CAR T-cell therapy market are mainly focusing on immunotherapies that are showing potential in standalone treatments and in administration in combination with other types of treatments.

BIRAC Acquires Recognition for Increasing Availability of CAR T-cell Therapy in India

The CAR T-cell therapy is emerging as a breakthrough innovation in cancer treatment. Clinical trials conducted globally are showing promising results in end stage patients and especially, for patients suffering from Acute Lymphocytic Leukemia. Such findings are translating into revenue opportunities for companies in the CAR T-cell therapy market. However, there is a need to increase the availability of CAR T-cell therapy in India. A possible way to increase its availability in India is by reducing the cost of the treatment.

The manufacturing complexity is a major reason for high therapy cost in India. In order to promote and support the development of CAR T-cell technology against cancer and other diseases, the Biotechnology Industry Research Assistance Council (BIRAC) is taking the initiative to invite proposals in India.

Health and Research Policy Frameworks Promote Innovations in Treatment Options

Since medicine continues to be revolutionized by advancements in treatments, CAR T-cell therapies are achieving increased commercialization. Such trends are contributing to the growth of the global CAR T-cell therapy market. For instance, Anixa Biosciences, Inc. is being known for its therapeutics profile in a cancer immunotherapy program, which uses chimeric endocrine receptor t-cell (CER-T) technology, a novel type of CAR-T.

CAR T-cell therapies are subject to health and research policy frameworks as well as legal regulations that have a direct influence on international competitiveness. Companies in the CAR T-cell therapy market are adhering to this design framework, which is an important instrument to support research in the EU and to promote innovations. It has been found that there are strict regulations in Germany for the import of medicinal products in order to ensure patient safety.

Analysts’ Viewpoint

Apart from gene therapy medicinal products, CAR T-cells holds promising potentials in the development of therapies for viral infections such as coronavirus. However, the high cost of CAR T-cell therapy in India is affecting market growth. Hence, companies in the India CAR T-cell therapy market should work closely with BIRAC and the Department of Biotechnology (DBT) to develop this technology in a cost effective manner whilst making it increasingly available for patients. The Tata Memorial Hospital (TMH), IIT Bombay team, and cancer care in India are gaining popularity for conducting the first CAR T-cell therapy at the bone marrow transplant unit at ACTREC, Tata Memorial Center in Mumbai.

CAR T-cell Therapy Market: Overview

Chimeric antigen receptors (CAR) are genetically engineered protein constructs that can be incorporated into a patient’s own cytotoxic T cells to help them to recognize and fight cancer cells

CAR T-cell therapy is used in the treatment of acute lymphocytic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, multiple myeloma, and others

Increase in incidence of cancer and strong product pipeline are projected to drive the global CAR T-cell therapy market

Increase in incidence of cancer is likely to boost the growth of the global CAR T-cell therapy market during the forecast period. Cancer is a leading cause of death across the world. Majority of cancer cases are caused due to lifestyle-related factors such as alcohol consumption, tobacco consumption, and some food-related factors such as nitrites and polyaromatic hydrocarbons. According to World Health Organization statistics, in 2020, an estimated 19.3 million new cases of cancer and 10.0 million deaths were reported across the globe.

Major market players focus on research & development to develop new CAR T-cell therapy products for treatment of different types of cancer. This is another major factor fueling the growth of the global CAR T-cell therapy market. Majority of CAR T clinical researches focus on hematological cancer (57%), followed by CNS (8%), GI (6%), skin (5%), genitourinary (4%), breast (4%), gynecologic (4%), respiratory (3%), sarcoma (2%), mesothelioma (2%), and others (5%).

Market Segmentation: CAR T-cell Therapy Market

In terms of product type, the global CAR T-cell therapy market has been classified into axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, lisocabtagene maraleucel, idecabtagene vicleucel, and others

Based on indication, the global CAR T-cell therapy market has been categorized into acute lymphocytic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, multiple myeloma, and others

In terms of end-user, the global CAR T-cell therapy market has been divided into hospitals and cancer treatment centers

Each of the segments has been analyzed in detail for CAR T-cell therapy trends, recent trends & developments, drivers, restraints, opportunities, and useful insights. The CAR T-cell therapy market report provides current and future revenue (US$ Mn) for each of these segments for the period from 2017 to 2031, considering 2020 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2021 to 2031 along with market size estimations.

Regional Overview: CAR T-cell Therapy Market

In terms of region, the global CAR T-cell therapy market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.

North America accounted for the largest share of the global CAR T-cell therapy market in 2020 and the trend is projected to continue during the forecast period. Growth of the CAR T-cell therapy market in North America can be primarily ascribed to presence of major players, significant healthcare expenditure, early availability of new techniques, and increase in research activities across the country.

Asia Pacific is anticipated to gain market share during the forecast period. Product launches, acquisitions, distribution agreements, alliances, and geographical expansion by local players, especially in China and India, are expected to propel the CAR T-cell therapy market in the region.

The current and future market sizes in terms of value (US$ Mn) of these regional markets and major countries have been provided in the report for the period from 2017 to 2031, along with CAGRs for the period from 2021 to 2031

The study also offers a list of recommendations, highlights, and useful insights of the market, which are estimated to help new companies willing to enter the market and existing companies to increase market share and in the decision-making process

Major Players

The report concludes with the company profiles section that includes key information about the major players in the global CAR T-cell therapy market

Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Key Questions Answered in CAR T-cell Therapy Market Report

  • What is the sales/revenue generated by CAR T-cell therapy across all regions during the forecast period?
  • What are the opportunities in the global CAR T-cell therapy market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which product type is expected to generate the highest revenue globally in 2031? Which segment is projected to expand at the highest CAGR during the forecast period?
  • What is the market position of different companies operating in the global market?

CAR T-cell Therapy Market – Segmentation

Product Type

  • Axicabtagene Ciloleucel
  • Tisagenlecleucel
  • Brexucabtagene Autoleucel
  • Lisocabtagene Maraleucel
  • Idecabtagene Vicleucel
  • Others

Indication

  • Acute Lymphocytic Leukemia
  • Diffuse Large B-cell lymphoma
  • Follicular Lymphoma
  • Mantle Cell Lymphoma
  • Multiple Myeloma
  • Others

End-user

  • Hospitals
  • Cancer Treatment Centers

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

TABLE OF CONTENT

1. Preface

    1.1. Report Scope and Market Segmentation

    1.2. Research Highlights

2. Assumptions and Research Methodology

    2.1. Assumptions and Acronyms Used

    2.2. Research Methodology

3. Executive Summary

4. Market Overview

    4.1. Introduction

    4.2. Market Dynamics

        4.2.1. Drivers

        4.2.2. Restraints

        4.2.3. Opportunity

    4.3. Global CAR T-cell Therapy Market Forecast

    4.4. Global CAR T-cell Therapy Market Outlook

5. Market Outlook

    5.1. Key Industry Events

    5.2. Diseases Epidemiology

    5.3. Product Pipeline Analysis

    5.4. Impact of COVID-19 Pandemic

6. Global CAR T-cell Therapy Market Analysis, by Product Type

    6.1. Introduction

    6.2. Global CAR T-cell Therapy Market Value Share Analysis, by Product Type

    6.3. Global CAR T-cell Therapy Market Forecast, by Product Type

        6.3.1. Axicabtagene Ciloleucel

        6.3.2. Tisagenlecleucel

        6.3.3. Brexucabtagene Autoleucel

        6.3.4. Lisocabtagene Maraleucel

        6.3.5. Idecabtagene Vicleucel

        6.3.6. Others

    6.4. Global CAR T-cell Therapy Market Analysis, by Product Type

    6.5. Global CAR T-cell Therapy Market Attractiveness Analysis, by Product Type

7. Global CAR T-cell Therapy Market Analysis, by Indications

    7.1. Introduction

    7.2. Global CAR T-cell Therapy Market Value Share Analysis, by Indication

    7.3. Global CAR T-cell Therapy Market Forecast, by Indication

        7.3.1. Acute Lymphocytic Leukemia

        7.3.2. Diffuse Large B-Cell Lymphoma

        7.3.3. Follicular Lymphoma

        7.3.4. Mantle Cell Lymphoma

        7.3.5. Multiple Myeloma

        7.3.6. Others

    7.4. Global CAR T-cell Therapy Market Analysis, by Indication

    7.5. Global CAR T-cell Therapy Market Attractiveness Analysis, by Indication

8. Global CAR T-cell Therapy Market Analysis, by End-user

    8.1. Introduction

    8.2. Global CAR T-cell Therapy Market Value Share Analysis, by End-user

    8.3. Global CAR T-cell Therapy Market Forecast, by End-user

        8.3.1. Hospitals

        8.3.2. Cancer Treatment Centers

    8.4. Global CAR T-cell Therapy Market Analysis, by End-user

    8.5. Global CAR T-cell Therapy Market Attractiveness Analysis, by End-user

9. Global CAR T-cell Therapy Market Analysis, by Region

    9.1. Global CAR T-cell Therapy Market Analysis, by Region

    9.2. Global CAR T-cell Therapy Market Value Share Analysis, by Region

    9.3. Global CAR T-cell Therapy Market Forecast, by Region

        9.3.1. North America

        9.3.2. Europe

        9.3.3. Asia Pacific

        9.3.4. Latin America

        9.3.5. Middle East & Africa

10. North America CAR T-cell Therapy Market Analysis

    10.1. North America CAR T-cell Therapy Market Overview

    10.2. North America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Country

    10.3. North America CAR T-cell Therapy Market Forecast, by Country

        10.3.1. U.S.

        10.3.2. Canada

    10.4. North America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Product Type

    10.5. North America CAR T-cell Therapy Market Forecast, by Product Type

        10.5.1. Axicabtagene Ciloleucel

        10.5.2. Tisagenlecleucel

        10.5.3. Brexucabtagene Autoleucel

        10.5.4. Lisocabtagene Maraleucel

        10.5.5. Idecabtagene Vicleucel

        10.5.6. Others

    10.6. North America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Indications

    10.7. North America CAR T-cell Therapy Market Forecast, by Indication

        10.7.1. Acute Lymphocytic Leukemia

        10.7.2. Diffuse Large B-Cell Lymphoma

        10.7.3. Follicular Lymphoma

        10.7.4. Mantle Cell Lymphoma

        10.7.5. Multiple Myeloma

        10.7.6. Others

    10.8. North America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by End-user

    10.9. North America CAR T-cell Therapy Market Forecast, by End-user

        10.9.1. Hospitals

        10.9.2. Cancer Treatment Centers

11. Europe CAR T-cell Therapy Market Analysis

    11.1. Europe CAR T-cell Therapy Market Overview

    11.2. Europe CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Country/Sub-region

    11.3. Europe CAR T-cell Therapy Market Forecast, by Country/Sub-region

        11.3.1. Germany

        11.3.2. France

        11.3.3. U.K.

        11.3.4. Italy

        11.3.5. Spain

        11.3.6. Rest of Europe

    11.4. Europe CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Product Type

    11.5. Europe CAR T-cell Therapy Market Forecast, by Product Type

        11.5.1. Axicabtagene Ciloleucel

        11.5.2. Tisagenlecleucel

        11.5.3. Brexucabtagene Autoleucel

        11.5.4. Lisocabtagene Maraleucel

        11.5.5. Idecabtagene Vicleucel

        11.5.6. Others

    11.6. Europe CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Indication

    11.7. Europe CAR T-cell Therapy Market Forecast, by Indication

        11.7.1. Acute Lymphocytic Leukemia

        11.7.2. Diffuse Large B-Cell Lymphoma

        11.7.3. Follicular Lymphoma

        11.7.4. Mantle Cell Lymphoma

        11.7.5. Multiple Myeloma

        11.7.6. Others

    11.8. Europe CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by End-user

    11.9. Europe CAR T-cell Therapy Market Forecast, by End-user

        11.9.1. Hospitals

        11.9.2. Cancer Treatment Centers

12. Asia Pacific CAR T-cell Therapy Market Analysis

    12.1. Asia Pacific CAR T-cell Therapy Market Overview

    12.2. Asia Pacific CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Country/Sub-region

    12.3. Asia Pacific CAR T-cell Therapy Market Forecast, by Country/Sub-region

        12.3.1. China

        12.3.2. Japan

        12.3.3. India

        12.3.4. Australia & New Zealand

        12.3.5. Rest of Asia Pacific

    12.4. Asia Pacific CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Product Type

    12.5. Asia Pacific CAR T-cell Therapy Market Forecast, by Product Type

        12.5.1. Axicabtagene Ciloleucel

        12.5.2. Tisagenlecleucel

        12.5.3. Brexucabtagene Autoleucel

        12.5.4. Lisocabtagene Maraleucel

        12.5.5. Idecabtagene Vicleucel

        12.5.6. Others

    12.6. Asia Pacific CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Indication

    12.7. Asia Pacific CAR T-cell Therapy Market Forecast, by Indication

        12.7.1. Acute Lymphocytic Leukemia

        12.7.2. Diffuse Large B-Cell Lymphoma

        12.7.3. Follicular Lymphoma

        12.7.4. Mantle Cell Lymphoma

        12.7.5. Multiple Myeloma

        12.7.6. Others

    12.8. Asia Pacific CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by End-user

    12.9. Asia Pacific CAR T-cell Therapy Market Forecast, by End-user

        12.9.1. Hospitals

        12.9.2. Cancer Treatment Centers

13. Latin America CAR T-cell Therapy Market Analysis

    13.1. Latin America CAR T-cell Therapy Market Overview

    13.2. Latin America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Country/Sub-region

    13.3. Latin America CAR T-cell Therapy Market Forecast, by Country/Sub-region

        13.3.1. Brazil

        13.3.2. Mexico

        13.3.3. Rest of Latin America

    13.4. Latin America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Product Type

    13.5. Latin America CAR T-cell Therapy Market Forecast, by Product Type

        13.5.1. Axicabtagene Ciloleucel

        13.5.2. Tisagenlecleucel

        13.5.3. Brexucabtagene Autoleucel

        13.5.4. Lisocabtagene Maraleucel

        13.5.5. Idecabtagene Vicleucel

        13.5.6. Others

    13.6. Latin America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Indication

    13.7. Latin America CAR T-cell Therapy Market Forecast, by Indication

        13.7.1. Acute Lymphocytic Leukemia

        13.7.2. Diffuse Large B-Cell Lymphoma

        13.7.3. Follicular Lymphoma

        13.7.4. Mantle Cell Lymphoma

        13.7.5. Multiple Myeloma

        13.7.6. Others

    13.8. Latin America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by End-user

    13.9. Latin America CAR T-cell Therapy Market Forecast, by End-user

        13.9.1. Hospitals

        13.9.2. Cancer Treatment Centers

14. Middle East & Africa CAR T-cell Therapy Market Analysis

    14.1. Middle East & Africa CAR T-cell Therapy Market Overview

    14.2. Middle East & Africa CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Country/Sub-region

    14.3. Middle East & Africa CAR T-cell Therapy Market Forecast, by Country/Sub-region

        14.3.1. GCC Countries

        14.3.2. South Africa

        14.3.3. Rest of Middle East & Africa

    14.4. Middle East & Africa CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Product Type

    14.5. Middle East & Africa CAR T-cell Therapy Market Forecast, by Product Type

        14.5.1. Axicabtagene Ciloleucel

        14.5.2. Tisagenlecleucel

        14.5.3. Brexucabtagene Autoleucel

        14.5.4. Lisocabtagene Maraleucel

        14.5.5. Idecabtagene Vicleucel

        14.5.6. Others

    14.6. Middle East & Africa CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Indication

    14.7. Middle East & Africa CAR T-cell Therapy Market Forecast, by Indication

        14.7.1. Acute Lymphocytic Leukemia

        14.7.2. Diffuse Large B-Cell Lymphoma

        14.7.3. Follicular Lymphoma

        14.7.4. Mantle Cell Lymphoma

        14.7.5. Multiple Myeloma

        14.7.6. Others

    14.8. Middle East & Africa CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by End-user

    14.9. Middle East & Africa CAR T-cell Therapy Market Forecast, by End-user

        14.9.1. Hospitals

        14.9.2. Cancer Treatment Centers

15. Competition Landscape

    15.1. Competition Matrix

    15.2. Company Profiles

        15.2.1. Pfizer Inc.

            15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.1.2. Product Portfolio

            15.2.1.3. Financial Overview

            15.2.1.4. SWOT Analysis

            15.2.1.5. Strategic Overview

        15.2.2. Novartis AG

            15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.2.2. Product Portfolio

            15.2.2.3. Financial Overview

            15.2.2.4. SWOT Analysis

            15.2.2.5. Strategic Overview

        15.2.3. Bristol-Myers Squibb

            15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.3.2. Product Portfolio

            15.2.3.3. Financial Overview

            15.2.3.4. SWOT Analysis

            15.2.3.5. Strategic Overview

        15.2.4. Amgen, Inc.

            15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.4.2. Product Portfolio

            15.2.4.3. Financial Overview

            15.2.4.4. SWOT Analysis

            15.2.4.5. Strategic Overview

        15.2.5. Sorrento Therapeutics, Inc.

            15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.5.2. Product Portfolio

            15.2.5.3. Financial Overview

            15.2.5.4. SWOT Analysis

            15.2.5.5. Strategic Overview

        15.2.6. Johnson & Johnson Services, Inc.

            15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.6.2. Product Portfolio

            15.2.6.3. Financial Overview

            15.2.6.4. SWOT Analysis

            15.2.6.5. Strategic Overview

        15.2.7. Gilead Sciences, Inc.

            15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.7.2. Product Portfolio

            15.2.7.3. Financial Overview

            15.2.7.4. SWOT Analysis

            15.2.7.5. Strategic Overview

        15.2.8. Merck & Co., Inc.

            15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.8.2. Product Portfolio

            15.2.8.3. Financial Overview

            15.2.8.4. SWOT Analysis

            15.2.8.5. Strategic Overview

        15.2.9. bluebird bio, Inc.

            15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.9.2. Product Portfolio

            15.2.9.3. Financial Overview

            15.2.9.4. SWOT Analysis

            15.2.9.5. Strategic Overview

Choose License Type

Checkout Inquiry Sample